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Background: Eldecalcitol is an analog of 1,25-dihydroxyvitamin D3 that improves bone mineral density;
however, the effect of eldecalcitol on the risk of fractures is unclear. The objective of this study is to examine
whether eldecalcitol is superior to alfacalcidol in preventing osteoporotic fractures. This trial is registered
with ClinicalTrials.gov, number NCT00144456.
Methods and results: This 3 year randomized, double-blind, active comparator, superiority trial tested the
efﬁcacy of daily oral 0.75 μg eldecalcitol versus 1.0 μg alfacalcidol for prevention of osteoporotic fractures.
1054 osteoporotic patients 46 to 92 years old were randomly assigned 1:1 to receive eldecalcitol (n=528) or
alfacalcidol (n=526). Patients were stratiﬁed by study site and serum 25-hydroxyvitamin D level. Patients
with low serum 25-hydroxyvitamin D levels (b50 nmol/L) were supplemented with 400 IU/day vitamin D3.
Primary end point was incident vertebral fractures. Secondary end points included any non-vertebral
fractures and change in bone mineral density and bone turnover markers. Compared with the alfacalcidol
group, the incidence of vertebral fractures was lower in eldecalcitol group after 36 months of treatment (13.4
vs. 17.5%; hazard ratio, 0.74; predeﬁned 90% conﬁdence interval [CI], 0.56–0.97). Eldecalcitol reduced
turnover markers and increased bone mineral density more strongly than alfacalcidol. Eldecalcitol reduced
the incidence of three major non-vertebral fractures, which was due to a marked reduction in wrist fractures
by a post-hoc analysis (1.1 vs. 3.6%; hazard ratio, 0.29; 95% CI, 0.11–0.77). Among the adverse events, the
incidence of increase in serum and urinary calcium was higher in the eldecalcitol group, without any
difference in glomerular ﬁltration rate between the two groups.
Conclusions: Eldecalcitol is more efﬁcacious than alfacalcidol in preventing vertebral and wrist fractures in
osteoporotic patients with vitamin D sufﬁciency, with a safety proﬁle similar to alfacalcidol.
© 2011 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Eldecalcitol (ED-71) is an analog of 1,25-dihydroxyvitamin D3
[1,25(OH)2D3] [1] that increases bone mass and bone strength in
rodents [2,3]. An open-label, controlled clinical trial in osteoporotic
patients demonstrated that, compared with baseline values, treat-
ment with 0.25 to 1.0 μg/day eldecalcitol for 6 months increasede and Bioregulatory Sciences,
ences, 3-18-15 Kuramoto-cho,
p (T. Matsumoto).
-NC-ND license.lumbar spine bone mineral density (BMD) in a dose-dependent
manner without causing sustained hypercalcemia or hypercalciuria
[4,5]. A double-blind, placebo-controlled clinical trial for 12 months
with vitamin D supplementation revealed that eldecalcitol increased
lumbar spine and total hip BMD in a dose-dependent manner, with a
lower incidence of hypercalcemia in the 0.75 μg/day eldecalcitol
group than in the highest dose (1.0 μg/day) group [6]. The effect of
eldecalcitol on the lumbar spine and total hip BMD was independent
of serum 25-hydroxyvitamin D levels (25(OH)D) [7], suggesting that
eldecalcitol can increase BMD regardless of the state of vitamin D
sufﬁciency.
A number of studies have examined the effect of alfacalcidol on the
incidence of fractures in osteoporotic patients. Althoughmost of those
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demonstrated that alfacalcidol treatment resulted in a signiﬁcant
reduction [8,9], while others did not show a signiﬁcant reduction
[10,11], in vertebral fracture incidence compared with a placebo.
However, the effect of eldecalcitol has not been compared head-to-
head with that of alfacalcidol.
An open-label clinical trial to compare the effect of eldecalcitol with
that of alfacalcidol on bone turnover and calcium (Ca) metabolism
showed that 0.5 to 1.0 μg/day eldecalcitol inhibits bone resorptionmore
than alfacalcidol, while their effects on bone formation markers and
urinaryCa excretionwere similar [12]. Thepresent studywas conducted
to compare the effect of eldecalcitol with that of alfacalcidol in
preventing vertebral fractures in men and women with osteoporosis.
Subjects and methods
Study design and patients
This was a randomized, active comparator, double-blind, superiority
trial of the effect of eldecalcitol versus alfacalcidol for reduction in
incidence of vertebral fractures. A total of 1054 patients (1030 females
and 24males, all Japanese) aged from 46 to 92 years (mean 72.1 years)
from 52 centers in Japan were enrolled between September 2004 and
August 2005, and randomly assigned to receive identical capsules of
either 0.75 μg eldecalcitol or 1.0 μg alfacalcidol once a day for
36 months. Adherence to the medications was monitored by counting
the remaining capsules at each visit, and wasmore than 95% in average
throughout the study period (96.5% in eldecalcitol and 95.7% in
alfacalcidol groups, respectively). Serum25(OH)Dmeasured byNichols
Allegro Lite (Nichols Institute, San Clemente, CA) was below 50 nmol/L
in 39.3% of the patients at enrollment (208 in eldecalcitol and 206 in
alfacalcidol group). These patients were given 400 IU/day vitamin D3
throughout the study period.
Patients without vertebral fractures were enrolled if their lumbar
spine or total hip BMD T-score was below−2.6 and they were 70 years
or older, or if their T-scorewas below−3.4 and theywere younger than
70 years. Patients with lumbar spine or total hip BMD T-score of below
−1.7were enrolled if theyhadbetweenoneandﬁvevertebral fractures.
Prevalent vertebral fractures at enrollment were assessed by lateral
spine X-ray examination of the thoracic and lumbar vertebrae, andwere
diagnosed quantitatively according to the criteria of the Japanese
Society for Bone and Mineral Research [13,14]. Women were at least
3 years after menopause or older than 60 years. Patients were excluded
if they had primary hyperparathyroidism, Cushing's syndrome, prema-
turemenopausedue tohypothalamic, pituitary or gonadal insufﬁciency,
poorly controlled diabetes mellitus (HbA1c over 9%) or other causes of
secondary osteoporosis, or had a history of urolithiasis. Patients were
also excluded if they had taken any oral bisphosphonates within
6 months before entry or for more than 2 weeks during the period 6 to
12 months before entry, or intravenous bisphosphonates at any time;
had taken glucocorticoids, calcitonin, vitamin K, active vitamin D
compounds, raloxifene, or hormone replacement therapy within the
previous 2 months; had serum Ca levels of above 10.4 mg/dL
(2.6 mmol/L) or urinary Ca excretion of over 0.4 mg/dL glomerular
ﬁltrate (GF) (0.1 mmol/L GF); had serum creatinine above 1.3 mg/dL
(115 μmol/L); or had clinically signiﬁcant hepatic or cardiac disorders.
The protocol was approved by the internal human studies review board
at each center, and informed consent was obtained from each patient.
Randomization and masking
Patients who satisﬁed all eligibility criteria were randomly assigned
in a 1:1 ratio to receive eldecalcitol or alfacalcidol. Treatment was
assigned by use of dynamic allocation, via a central enrollment center.
The randomization sequence was created by the person responsible for
investigational product randomization. Randomizationwas stratiﬁedbystudy site with minimization for 25(OH)D level (b50 nmol/L,
≥50 nmol/L) at provisional enrollment. Both patients and investigators
weremasked to treatment assignment throughout the study follow-up.Procedures
The primary end point was incident vertebral fractures. Secondary
end points included any non-vertebral fractures, changes in bone
mineral density of the total hip and lumbar spine, and changes in bone
turnover markers. All investigators who performed end point evalua-
tions were unaware of the study-group assignments of patients.
Lateral radiographs of the thoracic and lumbar spine were taken at
baseline and at 6, 12, 24, and 36 months or at termination. Three expert
investigators independently evaluated vertebrae from T4 to L4.
Prevalent fractures were assessed semiquantitatively as grades 0 to 3
[15]. Incident vertebral fractures were diagnosed quantitatively if the
anterior, posterior, or middle vertebral height had decreased by at least
15% and by≥4 mm in a vertebra that was assessed at baseline as grade
0, 1, or 2 [16]. If the investigators' assessments disagreed, the ﬁnal
assessment was made after conference by all the investigators. Seven
subgroups due to age, serum 25(OH)D, the presence or absence, the
number, and the semi-quantitative grade of prevalent vertebral
fractures, lumbar spine BMD, and total hip BMD were predeﬁned to
test for interaction.
All non-vertebral fractures were identiﬁed symptomatically as
clinical fractures. Suspected non-vertebral fractures without excessive
trauma assessed centrally were conﬁrmed radiographically. Subgroup
analyses were predeﬁned at major six non-vertebral sites (clavicle,
humerus, wrist, pelvis, hip and leg) andmajor three non-vertebral sites
(humerus, wrist and hip).
Dual-energy X-ray absorptiometry (DXA) measurements of the
lumbar spine BMD (posteroanterior projection) and the total hip were
made at baseline and at 6, 12, 24, and 36 months. T-scorewas calculated
based upon the database from nationwide survey [13]. A central facility
performed quality assurance of the longitudinal adjustment, by
calibrating each machine with standardized phantoms. All DXA
measurements were analyzed at a central site by a radiologist blinded
to treatment group assignment.
Serumand postprandial urine sampleswere collected at baseline, 0.5,
1, and 2 months, and every secondmonth thereafter until 36 months for
routine analyses, including Ca concentrations. At baseline, 6, 12, 24, and
36 months, we determined serum bone-speciﬁc alkaline phosphatase
(BSAP) (Metra-BAP EIA; Quidel, San Diego, CA; reference range 7.9 to
29.0 U/L) and urinary type I collagen N-telopeptide (NTX) (Osteomark;
Inverness Medical Innovations, Waltham, MA; reference range 9.3 to
54.3 nmol BCE/mol Cr) as bone turnover markers, and 25(OH)D (HPLC-
competitive protein binding assay), 1,25(OH)2D (HPLC radioreceptor
assay) and intact parathyroid hormone (PTH) (Eclusys PTH, Roche
Diagnostics, Penzberg, Germany) as calcium-regulating hormones.
Nichols Allegro Lite was used for the measurement of 25(OH)D only at
enrollment, because manufacturing of the kit was discontinued
thereafter. Regression analysis between the twomeasurements revealed
that there was a linear relationship between the 25(OH)D values from
HPLC-competitive binding assay (y) and Nichols Allegro Lite assay (x):
y=1.016x+4.555.
If increase in serum Ca over 11.0 mg/dL (2.75 mmol/L) developed, or
if increase in serumCa over 10.4 mg/dL (2.6 mmol/L) alongwith urinary
Ca over 0.4 mg/dL GF (0.1 mmol/L GF) developed, treatment was
discontinued. If serum Ca in these patients subsequently decreased to
below 10.4 mg/dL (2.6 mmol/L) and urinary Ca decreased to below
0.4 mg/dL GF (0.1 mmol/L GF), treatment was resumed with reduced
doses (0.5 μgeldecalcitol andalfacalcidol). Fifteenpatients in eldecalcitol
group, and 12 patients in alfacalcidol group discontinued treatment.
Among them, all 15 patients in eldecalcitol group and 9 patients in
alfacalcidol group resumed treatment with reduced doses. Compliance
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diaries and counts of residual medication supplies.
All patients were questioned about adverse events at each visit,
and all adverse events were analyzed regardless of the investigators'
assessments of causality. The Medical Dictionary for Regulatory
Activities (MedDRA, Version 8) was used to categorize reported
adverse events.
Statistical analysis
All randomized patients who took any dose of a study drug were
included in the safety analysis, and all randomized patients with drug
administration who had a baseline assessment and at least one post-
randomization assessment were included in the efﬁcacy analysis
(Fig. 1).
Analysis of vertebral fracture incidence included patients who
underwent radiography at baseline and at least once during the study
period. The incidence of new vertebral fractures was analyzed by a log-
rank test stratiﬁed by the number of prevalent vertebral fractures at
baseline. Kaplan–Meier estimates of new vertebral fracture incidence
were calculated at times when radiography was performed. A stratiﬁed
proportional hazard model was used to estimate relative risks and 95%
conﬁdence intervals. Reported P values are deﬁned by a two-sided alpha
of 0.05, except for the primary endpoint in which signiﬁcance was
deﬁned by a two-sided alpha of 0.10 with 90% conﬁdence intervals.
This study examining the superiority of eldecalcitol over alfacalcidol
in vertebral fracture prevention had a power of 90% to detect a 35%1318 Patients under
528 Underwent safety analysis
526 Underwent efficacy analysis
1087 Underwent r
427 Completed 3 years
101 Discontinued study
42 Withdrew consent
31 Had adverse event
9 Had disease progression
19 Had other reasons
15 Did not receive drug
543 Were assigned to receive eldecalcitol
528 Received drug
15 Did not receive drug
Fig. 1. Enrollment and outcomes. The 33 patients in both groups who did not receive a study
who were ineligible for inclusion at baseline or did not have any efﬁcacy data were excludreduction in risk of morphometric vertebral fractures by eldecalcitol,
assuming a 3-year incidence of 22.5% in the alfacalcidol group with 421
patients. Serum25(OH)D at baselinewas added as a stratiﬁcation factor
when primary analyses were conducted. Two-sided Student's t-tests
were used to determine the intergroup differences in changes of BMD
and bone turnover markers. No adjustments were made for multiple
comparisons of all endpoints. No methods of imputation were used for
missing data. The incidence of adverse events was compared by risk
ratio. Results on spinal radiographs, BMD, biochemical markers, and
other variables were collected centrally and transferred to the sponsor
for statistical analyses. Seven pre-speciﬁed subgroups were analyzed
with a stratiﬁed proportional hazard model to evaluate the interactions
between treatments and subgroups with respect to the risk of incident
vertebral fractures. We report the results of all these analyses. P values
were calculated by log likelihood test. Statistical analyses were
performed by statisticians from the sponsor, and the analyses were
conﬁrmed by an outside institution. The authors had access to all the
data and take responsibility for the veracity of the analyses.
Results
There were no statistically signiﬁcant differences in baseline
characteristics between the eldecalcitol and the alfacalcidol groups
(Table 1). Incident vertebral fractures occurred in 64 eldecalcitol-
treated and 80 alfacalcidol-treated patients during the 36-month
treatment period. Kaplan–Meier estimates of risk after 36 months
were 13.4% in the eldecalcitol group and 17.5% in the alfacalcidol group,went screening
231 Were excluded
110 Were not eligible
121 Had other reasons
andomization
526 Underwent safety analysis
523 Underwent efficacy analysis
410 Completed 3 years
116 Discontinued study
47 Withdrew consent
40 Had adverse event
7 Had disease progression
22 Had other reasons
18 Did not receive drug
544 Were assigned to receive alfacalcidol
526 Received drug
18 Did not receive drug
drug at baseline were excluded from the safety analysis; 5 patients in the safety analysis
ed from the efﬁcacy analysis.
Table 1
Baseline characteristics of enrolled patients.
Eldecalcitol
(n=528)
Alfacalcidol
(n=526)
Age (years) 72.2 (6.60) 72.1 (6.64)
Height (cm) 149 (5.76) 149 (6.04)
Male patients 9 (1.70%) 15 (2.85%)
Body mass index (kg/m2) 22.2 (3.19) 22.3 (3.20)
Time since menopause (years) 22.5 (7.78) 22.7 (7.69)
Number of prevalent vertebral fractures 1.18 (1.28) 1.25 (1.36)
0 199 (37.7%) 194 (36.9%)
1 156 (29.5%) 160 (30.4%)
≥2 173 (32.8%) 172 (32.7%)
Lumbar bone mineral density T-score −2.71 (0.94) −2.71 (0.91)
(n=527) (n=526)
Total hip bone mineral density T-score −2.26 (0.82)
(n=486)
−2.27 (0.79)
(n=485)
Serum bone-speciﬁc alkaline phosphatase (U/L) 33.3 (14.4) 33.8 (12.6)
Urinary type I collagen N-telopeptide
(nmol BCE/mol Cr)
58.1 (58.6) 56.9 (32.7)
Ca intake (mg/day) 714 (343) 734 (337)
Serum 25(OH)D (HPLC-CPBA, nmol/L) 68.9 (22.3) 67.8 (22.0)
Serum 1,25(OH)2D (pmol/L) 123.8 (35.3) 123.9 (37.9)
Serum intact PTH (pg/mL) 37.6 (15.1) 38.6 (14.3)
Data are means (SD) or number (%).
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Fig. 2. Incidence of new vertebral fractures during the 3-year study period. Kaplan–
Meier estimates of the incidence of new vertebral fractures (Panel A), the annual
incidence of new vertebral fractures (Panel B) are shown for both study groups.
608 T. Matsumoto et al. / Bone 49 (2011) 605–612with a relative risk reduction of 26% by eldecalcitol (P=0.092; 90% CI,
0.56–0.97) (Fig. 2A). The incidence of new vertebral fracture was not
different between the two groups during the ﬁrst 12 months; however,
it was signiﬁcantly lower in the eldecalcitol group during the third year
(odds ratio 0.51; P=0.037; 95% CI, 0.27–0.97) (Fig. 2B).
Eldecalcitol increased lumbar spine BMD by 2.3 percentage points at
12 months (Pb0.001) and 3.3 percentage points at 36 months com-
pared with alfacalcidol (Pb0.001) (Fig. 3A). Eldecalcitol also increased
total hip BMD by 1.4 percentage points at 12 months (Pb0.001) and 2.7
percentage points at 36 months (Pb0.001) compared with alfacalcidol
(Fig. 3B).
Compared with alfacalcidol, eldecalcitol decreased serum BSAP by
17 percentage points at 12 months (Pb0.001) and 18 percentage points
at 36 months (Pb0.001) (Fig. 3C). Urinary NTX was also signiﬁcantly
lowerwith eldecalcitol thanwith alfacalcidol by 29 percentage points at
12 months (Pb0.001) and by 23 percentage points at 36 months
(Pb0.001) (Fig. 3D).
Serum 25(OH)D levels were elevated from baseline to 83.0 (SE 1.0)
and 86.2 (1.0) nmol/L in eldecalcitol and alfacalcidol groups, respec-
tively, at 6 months and remained at similar levels throughout the study
(Fig. 4A). As a result, serum 25(OH)D levels were over 50 nmol/L in
more than 92% of the patients during the study period. Serum 1,25
(OH)2D was suppressed sharply to 65.7 (SE 1.5) pmol/L in eldecalcitol
group, whereas it was modestly elevated to 138 (1.6) in alfacalcidol
group at 6 months, and remained almost stable during the study in both
groups (Fig. 4B). Serum intact PTH levels were suppressed at 6 months
in both groups, but the suppressionwas less in eldecalcitol group than in
alfacalcidol group (Fig. 4C), as reported previously [7,12].
No signiﬁcant difference was observed between the eldecalcitol
and alfacalcidol groups in the incidence of total non-vertebral
fractures at 36 months (8.0 and 9.5%, respectively; hazard ratio,
0.85; 95%CI, 0.55–1.31). Analysis of the two pre-deﬁned subgroups
revealed that the incidence of non-vertebral fractures tended to be
lower at themajor three sites (2.5 and 4.9%, respectively; hazard ratio,
0.51; 95% CI, 0.25–1.03). Post-hoc analysis of the fracture incidence in
each of the three sites (humerus, wrist and hip) revealed that the
incidence of only wrist fracture was signiﬁcantly lower in the
eldecalcitol group than in the alfacalcidol group at 36 months (1.1
and 3.6%, respectively; hazard ratio, 0.29; 95%CI, 0.11–0.77;
P=0.009) (Fig. 5). No signiﬁcant difference between the two groups
was observed in the fracture incidence of any other non-vertebral
sites.Adverse events with more than 5% incidence in either of the two
groups are listed in Table 2. Urinary Ca excretion increased in both the
eldecalcitol and alfacalcidol groups;meanpostprandial urinaryCa levels
at 36 months were 0.242 and 0.209 mg/dL GF (0.061 and
0.052 mmol/L GF), respectively. The increase in urinary Ca was not
associated with a decrease in estimated glomerular ﬁltration rate
(eGFR) throughout the study period (69.0±13.6 and 68.4±14.5 at
baseline, and 65.8±14.4 and 66.7±14.3 at 36 monthswith eldecalcitol
and alfacalcidol, respectively; means±SD). Increase in serum Ca over
10.4 mg/dL was observed at least once in the study in 111 and 71
patients, in eldecalcitol and alfacalcidol groups, respectively. Patients
with hypercalcemia over 11.5 mg/dL (2.875 mmol/L) at least once
during the study numbered 2 and 0 in the eldecalcitol and alfacalcidol
groups, respectively. Serum and urinary Ca returned to baseline levels
within 1 month after the study period (Supplement 1). The incidence of
constipation and exanthemwas lower in eldecalcitol than in alfacalcidol
group (Table 2). There was no signiﬁcant difference in the incidence of
any other adverse events between the eldecalcitol and alfacalcidol
groups.
Analyses of the seven pre-speciﬁed subgroups revealed that there
were no signiﬁcant interactions between treatment effect and any
baseline clinical ﬁndings. Among patients with two or more prevalent
vertebral fractures, the hazard ratio for incident vertebral fractures was
0.61 (95% CI, 0.40–0.93) in favor of eldecalcitol over alfacalcidol. The
hazard ratio for incident vertebral fractures among patients with a total
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Fig. 3. Bone mineral density (BMD), and bone turnover markers during the 3-year study period. BMD of the lumbar spine (Panel A) and total hip (Panel B), and biochemical markers
of bone turnover including serum bone-speciﬁc alkaline phosphatase (BSAP) (Panel C) and urinary N-terminal propeptide of type I collagen (NTX) (Panel D) are shown for both
study groups. Data are means±SE for lumbar spine and hip BMD, and medians for bone turnover markers. *Pb0.001 in comparison with alfacalcidol.
609T. Matsumoto et al. / Bone 49 (2011) 605–612hip BMD T-score of less than −2.5 was 0.56 (95% CI, 0.34–0.90),
indicating the superior effect of eldecalcitol among patients with low
total hip BMD (Fig. 6).
Discussion
This 3-year trial demonstrated that eldecalcitol decreased the risk of
vertebral fractures more than did alfacalcidol. Subgroup analyses
suggested that the effect of eldecalcitol on reducing risk of vertebral
fractures is greater in patients with more severe osteoporosis, indicated
by total hip BMD T-scores of less than−2.5 or multiple fractures.
The effect of alfacalcidol on vertebral fracture incidence has been
examined. Some studies reported positive results [8,9], while others did
not show a signiﬁcant reduction in vertebral fractures with alfacalcidol
[10,11]. A previous meta-analysis reported that active and native
vitamin D3 reduced the risk of vertebral fracture [17]. However, that
analysis did not have the power to distinguish the effect of alfacalcidol
and 1,25(OH)2D3 from that of native vitamin D3, and the effect of active
vitamin D3 was inﬂuenced by one large study using 1,25(OH)2D3 [18].
Thus, controversy remained as to the anti-fracture effect of active
vitamin D3. In the present study, patients with serum 25(OH)D below
50 nmol/Lwere supplementedwith 400 IU vitamin D3 daily, and serum25(OH)Dwas over 50 nmol/L inmore than 92% of the patients. Because
the anti-fracture effect of eldecalcitol was observed among vitamin D-
sufﬁcient osteoporotic patients, the effects of eldecalcitol on fractures, as
well as on BMD [6], were unlikely to be the effect of supplementing for
vitamin D insufﬁciency.
Eldecalcitol reduced vertebral fracture incidence with a suppression
of urinary NTX as a bone resorptionmarker. As to themechanism of the
suppression of bone resorption, eldecalcitol was shown to reduce the
number of preosteoblastic cells which interact with osteoclast pre-
cursors, resulting in a reduction in thenumber andactivity of osteoclasts
on the bone surface [19]. In agreement with these observations, in vivo
administration of eldecalcitol to mice reduced perimeter of receptor
activator of NF-kB ligand-positive cell surface around the trabecular
bone (Saito H, et al. personal communication). These results are
consistent with the notion that eldecalcitol suppresses the formation
and activation of osteoclastsmainly via its effect on preosteoblastic cells.
In addition topreventingvertebral fractures, eldecalcitol reduced the
incidence of wrist fracture, but had no signiﬁcant effect on other non-
vertebral fractures. There are twopossibilities to explain at least a part of
the effect on wrist fracture. First, we recently reported using clinical CT
that eldecalcitol improved hip geometry better than alfacalcidol by
increasing cross-sectional area, volumetric BMD, and cortical thickness
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Table 2
Incidence of adverse events.
Eventa Eldecalcitol
(N=528)
Alfacalcidol
(N=526)
Risk
ratio
95% CI
No. of patientsb
General
Any adverse events 520 (98.5%) 518 (98.5%) 1.00 0.99–1.02
Nasopharyngitis 332 (62.9%) 312 (59.3%) 1.06 0.96–1.17
Contusion 119 (22.5%) 118 (22.4%) 1.00 0.80–1.26
Urine calcium increased 135 (25.6%) 82 (15.6%) 1.64 1.28–2.10
Blood calcium increased 111 (21.0%) 71 (13.5%) 1.56 1.19–2.04
Back pain 72 (13.6%) 81 (15.4%) 0.89 0.66–1.19
Osteoarthritis 82 (15.5%) 70 (13.3%) 1.17 0.87–1.57
Arthralgia 54 (10.2%) 52 (9.9%) 1.03 0.72–1.48
Eczema 54 (10.2%) 50 (9.5%) 1.08 0.75–1.55
Constipation 39 (7.4%) 58 (11.0%) 0.67 0.45–0.99
Headache 51 (9.7%) 39 (7.4%) 1.30 0.87–1.94
Diarrhea 50 (9.5%) 38 (7.2%) 1.31 0.88–1.96
Gastroenteritis 46 (8.7%) 41 (7.8%) 1.12 0.75–1.67
Periarthritis 45 (8.5%) 41 (7.8%) 1.09 0.73–1.64
Spinal fracture 38 (7.2%) 46 (8.7%) 0.82 0.54–1.24
Cystitis 36 (6.8%) 44 (8.4%) 0.82 0.53–1.24
Hypertension 41 (7.8%) 36 (6.8%) 1.13 0.74–1.75
Gastritis 34 (6.4%) 40 (7.6%) 0.85 0.54–1.32
Pain in extremity 31 (5.9%) 40 (7.6%) 0.77 0.49–1.21
Stomatitis 37 (7.0%) 32 (6.1%) 1.15 0.73–1.82
Dermatitis contact 38 (7.2%) 28 (5.3%) 1.35 0.84–2.17
Insomnia 34 (6.4%) 32 (6.1%) 1.06 0.66–1.69
Dizziness 29 (5.5%) 32 (6.1%) 0.90 0.55–1.47
Cataract 32 (6.1%) 27 (5.1%) 1.18 0.72–1.94
Joint sprain 29 (5.5%) 28 (5.3%) 1.03 0.62–1.71
Spinal osteoarthritis 23 (4.4%) 34 (6.5%) 0.67 0.40–1.13
Stomach discomfort 27 (5.1%) 25 (4.8%) 1.08 0.63–1.83
Exanthem 15 (2.8%) 33 (6.3%) 0.45 0.25–0.82
Serious adverse events 110 (20.8%) 134 (25.5%) 0.82 0.66–1.02
Death 4 (0.8%) 6 (1.1%) 0.66 0.19–2.34
Cancer 11 (2.1%) 16 (3.0%) 0.68 0.32–1.46
Discontinued due to adverse events 31 (5.9%) 40 (7.6%) 0.77 0.49–1.21
Calcium-related adverse events
Urolithiasis 7 (1.3%) 5 (1.0%) 1.39 0.45–4.37
a Data are compiled using ICH Medical Terminology MedDRA Ver 8.0.
b All data are reported as number of patients (%).
610 T. Matsumoto et al. / Bone 49 (2011) 605–612by mitigating endocortical bone resorption [20]. Therefore, eldecalcitol
may have a better effect in improving biomechanical properties of long
bones. However, direct assessment of the effect of eldecalcitol on radialgeometry is required to clarify this issue. Second, although the incidence
of falls was not monitored in the present study, there have been reports
demonstrating the effect of vitamin D supplementation or active
vitamin D treatment in reducing the risk of falls [21,22], and the effect
wasmediated by an improvementof postural anddynamic balance [23].
In addition, higher serum 1,25(OH)2D3 concentrations were associated
with lower fall rates [24]. Because vitamin D receptor-deﬁcient mice
exhibit vestibular dysfunction with poor balance/posture control [25],
and because Bsm1 polymorphism of vitamin D receptor gene is
associatedwith the risk of falls [26], the effect of vitamin D on vestibular
function and falls appears to be mediated via vitamin D receptor. Thus,
there is a possibility that eldecalcitol may have a stronger effect than
Alfacalcidol
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32/204
48/319
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54/171
10/193
70/330
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0.996 
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Fig. 6. Analysis for heterogeneity of treatment effect according to baseline characteristics. Subgroup analysis of the effect of eldecalcitol in comparison with alfacalcidol on vertebral
fractures is shown according to seven pre-speciﬁed baseline characteristics.
611T. Matsumoto et al. / Bone 49 (2011) 605–612alfacalcidol in preventing falls. Further studies to compare the effect of
eldecalcitol with that of alfacalcidol on the risk of falls can clarify these
issues, as well as the reasons why eldecalcitol treatment reduced the
incidence of wrist fractures.
Serum 1,25(OH)2D was suppressed by about 50% in eldecalcitol
group, probably due to the suppressive effect of eldecalcitol on 25
(OH)D-1α-hydroxylase, while the suppression of serum intact PTH by
eldecalcitol was less than that by alfacalcidol as reported previously
[6,12]. Therefore, the stronger suppression of bone turnover by
eldecalcitol cannot be explained by a suppression of PTH levels.
Previous studies in animals revealed that eldecalcitol showed a
stronger effect than alfacalcidol on bone comparedwith that on serum
or urinary Ca [3,5]. Taken together, it is plausible to assume that
eldecalcitol exerts a stronger suppression of bone turnover and a
larger increase in BMD than alfacalcidol with similar effect on serum
and urinary Ca, resulting in the superior effect in preventing vertebral
and possibly wrist fractures.
It should be noted that the suppression of serum intact PTH and BSAP
levelswasmaximumafter 6 monthsof treatment bybotheldecalcitol and
alfacalcidol, and both of these levels tended to rise after 6 months. This
was not due to changes in vitaminD or Cametabolism, because serum25
(OH)D and 1,25(OH) 2D were stable after 6 months of treatment, and
serum and urinary Ca levels remained almost unchanged throughout the
study period (Supplement 1). Thus, the reason for the dissipation of the
suppressive effect of both eldecalcitol and alfacalcidol on intact PTH and
BSAP levels after 6 months of treatment remains unclear.
The present study included 24 male patients; 9 of them were in
eldecalcitol group and 15 of them were in alfacalcidol group. Incident
vertebral fracture occurred in one out of 9males and 2 out of 15males in
eldecalcitol and alfacalcidol groups, respectively. Mean changes in
lumbar BMDwere 10.9 and−0.24 percentage points after 36 months oftreatmentwith eldecalcitol and alfacalcidol, respectively.Mean changes
in total hip BMDwere 1.8 and−0.61 percentage points after 36 months
of treatment with eldecalcitol and alfacalcidol, respectively. From these
results, the effect of eldecalcitol may be superior among males as well.
However, thenumberof subjectswas too small to drawany conclusions,
and larger studies are needed to clarify this issue.
There was no signiﬁcant difference in the incidence of any adverse
events, and the number of serious adverse events was smaller in the
eldecalcitol-treated group. Although the incidence of urinary Ca
increase over 0.4 mg/dL GF was higher in the eldecalcitol group, the
incidence of urolithiasis was the same and no signiﬁcant difference in
eGFR was observed between the two groups. In addition, the incidence
of hypercalcemia of greater than 11.5 mg/dL was low in both groups (2
and 0 in the eldecalcitol and alfacalcidol groups, respectively). These
results demonstrate that eldecalcitol is safe for at least 3 years.
The present study has limitations. First, the present study lacked a
placebo group. Second, as a limitation relating to the size of the study
as an active comparator study, the statistical signiﬁcance of the
primary endpoint was predeﬁned as a two-sided alpha of 0.10 with
90% conﬁdence interval. Finally, although there was no statistical
difference in the incidence of hypercalcemia over 11.5 mg/dL or
urolithiasis between the eldecalcitol and alfacalcidol groups, the
incidence of increase in serum and urinary Ca was signiﬁcantly higher
in the eldecalcitol group. Therefore, the long-term safety of eldecalci-
tol needs to be studied.
In conclusion, in vitamin D-sufﬁcient patients with osteoporosis,
daily treatment with 0.75 μg eldecalcitol for 3 years is associated with a
lower risk of vertebral and wrist fractures, greater improvements in
lumbar spine BMD, and greater decreases in bone turnover than daily
treatment with 1.0 μg alfacalcidol. The long-term efﬁcacy and safety
remains to be studied.
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